The development of CETP (cholesteryl ester transfer protein) inhibitors has had a long and
difficult course with 3 compounds failing in phase III clinical trials. Finally, the REVEAL …

Atherosclerosis, the pathological basis of most cardiovascular disease (CVD), is closely
associated with cholesterol accumulation in the arterial intima. Excessive cholesterol is …

Progress in the modification of conventional coronary risk factors and lifestyle behavior has
reduced the incidence of atherosclerotic coronary artery disease; nonetheless, it continues …

High-density lipoprotein (HDL) is a complex mixture of lipoproteins that is associated with
many minor proteins and lipids that influence the function of HDL. Although HDL is a …

Adding to the foundation of statins, ezetimibe and proprotein convertase subtilisin–kexin
type 9 inhibitors (PCSK9i), novel, emerging low-density lipoprotein cholesterol (LDL-C) …

Background Dyslipidaemia remains a significant risk factor for cardiovascular disease and
additional lipid-modifying treatments are warranted to further decrease the cardiovascular …

Low high‐density lipoprotein (HDL)‐cholesterol levels are associated with an increased risk
of coronary artery disease (CAD) and myocardial infarction, which has triggered the …

Cholesteryl ester transfer protein (CETP) facilitates the exchange of cholesteryl esters and
triglycerides (TG) between high-density lipoprotein (HDL) particles and TG-rich …

Aims High-density lipoprotein cholesterol (HDL-C) is inversely associated with
cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of …

Coronary artery disease, the leading cause of death in the developed and develo**
countries, is prevalent in diabetes mellitus with 68% cardiovascular disease (CVD)-related …